Understanding and overcoming resistance in melanoma treatments
Core B: Biospecimen Repository and Processing Core
['FUNDING_P01'] · UNIVERSITY OF CALIFORNIA LOS ANGELES · NIH-10878837
This study is looking to make treatments for metastatic melanoma better by understanding why some tumors resist therapy, and it's for patients who are receiving different types of treatments, as it collects and analyzes samples from their tumors to help improve future care.
Quick facts
| Phase | ['FUNDING_P01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF CALIFORNIA LOS ANGELES (nih funded) |
| Locations | 1 site (LOS ANGELES, UNITED STATES) |
| Trial ID | NIH-10878837 on ClinicalTrials.gov |
What this research studies
This research focuses on improving treatments for metastatic melanoma by investigating the mechanisms behind tumor resistance to therapies. It aims to centralize the collection and analysis of high-quality biospecimens, such as tissues and cell lines, from patients undergoing various treatments, including targeted therapies and checkpoint inhibitors. By developing advanced techniques to analyze these samples, the research seeks to enhance our understanding of the tumor microenvironment and improve treatment outcomes for patients. The Biospecimen Repository and Processing Core will play a crucial role in supporting these efforts.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with metastatic melanoma who are undergoing or have undergone treatment with BRAF/MEK inhibitors or checkpoint inhibitors.
Not a fit: Patients with early-stage melanoma or those not receiving the specified treatments may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for melanoma, potentially overcoming resistance and improving patient outcomes.
How similar studies have performed: Other research has shown success in utilizing biospecimen repositories to enhance understanding of cancer treatments, making this approach both relevant and promising.
Where this research is happening
LOS ANGELES, UNITED STATES
- UNIVERSITY OF CALIFORNIA LOS ANGELES — LOS ANGELES, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: COMIN-ANDUIX, BEGONYA — UNIVERSITY OF CALIFORNIA LOS ANGELES
- Study coordinator: COMIN-ANDUIX, BEGONYA
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.